Loading...
Market
Will Merck acquire another ophthalmology company by 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Merck's press releases or major financial news outlets
Story
Merck to Acquire Kate Bingham-Backed EyeBio for Up to $3 Billion
May 29, 2024, 10:43 AM
Merck & Co., known as MSD outside of the United States and Canada, has announced a definitive agreement to acquire the Kate Bingham-backed ophthalmology-focused biotechnology company EyeBio for up to $3 billion. The deal includes an upfront payment of $1.3 billion, with an additional $1.7 billion contingent on milestone achievements. EyeBio, a clinical-stage company, is developing treatments for common eye diseases, including the Restoret drug for retinal diseases, and will enter late-stage clinical testing in the coming months. This acquisition marks Merck's continued efforts to expand its presence in the ophthalmology sector.
View original story
Similar markets
Less than 10% • 33%
10% to 20% • 33%
More than 20% • 33%
No milestones achieved • 33%
Only first milestone achieved • 33%
All milestones achieved • 33%
1-2 acquisitions • 33%
3-5 acquisitions • 33%
More than 5 acquisitions • 34%
Bristol Myers Squibb • 25%
Gilead Sciences • 25%
Novartis • 25%
Other • 25%
